NEWLY APPROVED HEAD AND NECK CANCER TREATMENT IMPROVES CARE FOR FIRST TIME IN MORE THAN 20 YEARS

The National Institute for Health and Care Excellence (NICE) has recommended an immunotherapy to treat advanced head and neck cancer for use on the NHS in England. In final draft guidance, published on 24 March 2026, NICE approved pembrolizumab (Keytruda; MSD), an IV infusion for patients with resectable locally advanced head and neck squamous cell […]

GLOBAL TRIAL SHOWS IMMUNOTERAPY DRUG FIGHT HEAD AND NECK CANCER

GLOBAL TRIAL SHOWS IMMUNOTERAPY DRUG FIGHT HEAD AND NECK CANCER Pembrolizumab, an immunotherapy drug, stimulates the immune system to fight cancer, targeting a specific protein that enables the drug to wipe out cancer cells. This is the biggest breakthrough in two decades. The drug kept cancer at bay in some patients for an average of […]